Camilla Sylvest
Camilla Sylvest is the executive vice-president of commercial strategy and corporate affairs at Novo Nordisk. In a recent interview, she discussed the company's commitment to investigating the health benefits of its semaglutide drug, particularly in relation to addiction and its potential role in reducing cravings, highlighting the ongoing research into the broader applications of GLP-1 medications.
Not in the pool (under ¢1).
Recent news mentions
Camilla Sylvest, the Novo Nordisk executive in charge of new drug roll-out, discussed the expected access to Wegovy.
Weight loss drug Wegovy to cost around €220 a month as supplies go on market in Ireland – The Irish Times
Ireland· 2025-03-25
Camilla Sylvest is the executive vice-president of commercial strategy and corporate affairs at Novo Nordisk, overseeing the launch of the obesity drug Wegovy in Ireland.
The obesity ‘wonderdrug’ comes to Ireland, but it will cost you – The Irish TimesIreland· 2025-03-21Camilla Sylvest, executive vice-president of commercial strategy and corporate affairs at Novo Nordisk, emphasized the company's commitment to pursuing health contributions of its semaglutide drug.
Novo Nordisk to explore how obesity drugs can help patients with addiction – The Irish TimesIreland· 2025-03-06